Biomedical research professional with expertise in large research collaborations, consortia, R&D alliances, IP asset portfolio management, medical product development partnerships, venture development, and seed funding. Over 25 years at the academic heath system-industry interface, with a record of operational excellence and closed deals. I specialize in new collaboration models and deal structures for scaling clinical data commons, biorepositories, novel tech development models (startup companies, academic enterprises, joint ventures), novel digital and genomic health product deployment models, & early stage capitalization of biomedical spinout companies.

I angel invest and co-invest in syndicated and side-car opportunities for limited sectors Series B and later with serial entrepreneurs and serial fund managers: deep tech, AI, blockchain, medical informatics. I leverage 15 years of leadership experience in large academic biomedical commercialization enterprises to catalyze new pathways to clinical validation, commercialization, and market adoption of new tech emerging from “Big Biology” and “Big Medicine” datasets, a hallmark of the PRECISION MEDICINE paradigm.

Wendy M. Charles, PhD, MS, CIP, CCRP is a clinical scientist, digital health leader, and educator with more than 25 years of experience spanning clinical research operations, regulatory compliance, health information technology, and emerging technologies in life sciences. She holds a PhD in Clinical Science with a specialty in Health Information Technology from the University of Colorado Anschutz Medical Campus and has led complex research and compliance programs across academic medical centers and digital health companies. Her expertise includes oncology and drug development research oversight, human subjects protection, FDA-regulated data integrity, real-world data strategies, and the ethical application of advanced technologies in clinical research.

Dr. Charles currently serves as an Assistant Professor of Health Informatics at the University of Denver and is Editor-in-Chief of the Frontiers in Blockchain: Blockchain for Science journal section. She has held executive leadership roles, including Chief Scientific Officer and Chief Ethics & Compliance Officer, and has advised pharmaceutical companies, venture capital firms, and international policy bodies on regulatory strategy, data governance, and technology-enabled research innovation. As a Scientific Advisory Board member for Bio-Path Holdings, Dr. Charles brings a translational perspective that bridges science, technology, and compliance to support the advancement of novel oncology therapeutics and the modernization of clinical research and data capture practices.

Quote:

“I am honored to join the Scientific Advisory Board at Bio-Path Holdings and am deeply inspired by the company’s innovative approach to advancing targeted oncology therapies. I look forward to contributing my experience in clinical research strategy, regulatory-grade data integrity, and emerging digital technologies to help strengthen development programs, support rigorous science, and accelerate the responsible translation of promising therapies to patients who need them most.”